Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Academisch Ziekenhuis Leiden (H O D N Lumc) is managing 5 pending office actions in the Medical Devices & Mechanical Engineering technology area. These actions are distributed across 4 distinct art units, indicating a broad technical range for a relatively small number of pending matters. The involvement of 4 distinct art units suggests that the company's medical device innovations are being evaluated by several different specialized groups.
The portfolio involves 5 distinct examiners, meaning each of the 5 pending office actions is assigned to a different person. REILLY, SOPHIA JANE is the busiest examiner, responsible for 1 pending office action. With 5 distinct examiners and 5 pending office actions, there is no examiner concentration, requiring the prosecution team to adapt to 5 different sets of examiner preferences. This lack of overlap across the 4 distinct art units may require a more diverse set of legal and technical arguments to satisfy the various examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (50%) |
| §103 only | 1 (17%) |
| §102 only | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REILLY, SOPHIA JANE | 1 | 60.8% | +49.2% |
| PORTER, JR, GARY A | 1 | 68.8% | +25.2% |
| LABRANCHE, BROOKE N | 1 | 72.7% | +15.7% |
| DELEO, VICTORIA LYNN | 1 | 41.4% | -44.4% |
| RAUBENSTRAW, TYLER ALLEN | 1 | 71.0% | +30.4% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18844633 | DHCR24 INHIBITORY COMPOUNDS | REILLY, SOPHIA JANE | — |
| 18237069 | SYSTEM, METHOD AND CATHETER FOR PITUITARY AND BRAIN IMPLANTATION | PORTER, JR, GARY A | — |
| 17919138 | METHODS FOR INDUCTION OF ENDOGENOUS TANDEM DUPLICATION EVENTS | DELEO, VICTORIA LYNN | — |
| 16521430 | T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | GUSTILO, ESTELLA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030356 | SURGICAL TOOL, SYSTEM AND METHOD | LABRANCHE, BROOKE N | 28d |
| 18844633 | DHCR24 INHIBITORY COMPOUNDS | REILLY, SOPHIA JANE | — |
| 18237069 | SYSTEM, METHOD AND CATHETER FOR PITUITARY AND BRAIN IMPLANTATION | PORTER, JR, GARY A | — |
| 17760105 | Apparatus for Prevention of Apnea | RAUBENSTRAW, TYLER ALLEN | — |
| 16521430 | T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 3796 | 1 |
| 3771 | 1 |
| 1662 | 1 |
| 3785 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844633 | DHCR24 INHIBITORY COMPOUNDS | REILLY, SOPHIA JANE | — | §103§112 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18237069 | SYSTEM, METHOD AND CATHETER FOR PITUITARY AND BRAIN IMPLANTATION | PORTER, JR, GARY A | 3796 | §101§102§103§112Other | Non-Final OA | — | Pending | Aug 23, 2023 |
| 18030356 | SURGICAL TOOL, SYSTEM AND METHOD | LABRANCHE, BROOKE N | 3771 | §102 | Non-Final OA | 28d | Pending | Apr 05, 2023 |
| 17919138 | METHODS FOR INDUCTION OF ENDOGENOUS TANDEM DUPLICATION EVENTS | DELEO, VICTORIA LYNN | 1662 | §101§102§103§112 | Final Rejection | — | Pending | Oct 14, 2022 |
| 17760105 | Apparatus for Prevention of Apnea | RAUBENSTRAW, TYLER ALLEN | 3785 | §103 | Non-Final OA | — | Pending | Aug 04, 2022 |
| 16521430 | T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | GUSTILO, ESTELLA M | 1646 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 24, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial